evaluation of minimal residual disease in acute myeloid leukemia with npm1 marker
نویسندگان
چکیده
background: minimal residual disease (mrd) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (aml) patients. approximately, 50% of aml patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid leukemia (cn-aml). about 60% of adult cn-aml has a mutation in exon 12 of npm1 gene. this mutation is specific for malignant clone and potentially is a good marker of mrd. in this retrospective study, we set up a quantitative test for quantifying npm1 type a mutation and aml patients carrying this mutation at the time of diagnosis, were followed-up. materials and methods : we prepared plasmids containing a cdna fragment of npm1 and abl genes by pcr cloning. the plasmids were used to construct standard curves. eleven patients were analyzed using established method. serial pb and/or bm samples (n=71) were taken in 1-3 months intervals (mean 1.5-month intervals) and median follow-up duration after chemotherapy was 11 months (5-28.5 months). results: in this study, we developed rna-based rq-pcr to quantitation of npm1 mutation a with sensitivities of 10 (-5) . the percent of npmmut/abl level showed a range between 132 and 757 with median of 383.5 in samples at diagnosis. the median npmmut transcript level log reduction was 3 logs. relapse occurred in 54.5% of patients (n=6), all cases at diagnosis demonstrated the same mutation at relapse. in patients who experienced relapse, log reduction levels of npm1 mrna transcript after therapy were 4 (n=2), 3 (n=2) and 1 log (n=2). totally, npmmut level showed less than 5 log reduction in all of them, whereas this reduction was 5-6 logs in other patients. conclusion : despite the limitations of this study in terms of sample size and duration of follow-up, it showed the accuracy of set up for detection of mutation and this marker has worth for following-up at different stages of disease. because of high frequency, stability, specificity to abnormal clone and high sensitivity, npm1 is a suitable marker for monitoring of npmc+ aml patients.
منابع مشابه
Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
BACKGROUND Minimal residual disease (MRD) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (AML) patients. Approximately, 50% of AML patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid leukemia (CN-AML). About 60% of adult CN-AML has a mutation in exon 12 of NPM1 gene. This mutation...
متن کاملDetection of minimal residual disease in acute myeloid leukemia.
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patien...
متن کاملMinimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manus...
متن کاملMinimal residual disease quantitation in acute myeloid leukemia.
The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous. A minority of patients have clinical and biologic features associated with a very high risk of relapse. For the remaining patients, no clear prognostic factors can be identified at diagnosis. The degree of treatment response is likely to be an informative predictor of outcome for these patients. Modern assays to dete...
متن کاملEvaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR
متن کامل
The relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia
Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۱۰، شماره ۳، صفحات ۱۴۷-۱۵۲
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023